about
Micro-scale devices for transdermal drug deliveryImmunoprevention of chemical carcinogenesis through early recognition of oncogene mutationsEvaluation of a novel non-penetrating electrode for use in DNA vaccinationDermaVir: a plasmid DNA-based nanomedicine therapeutic vaccine for the treatment of HIV/AIDS.Surfactant sodium lauryl sulfate enhances skin vaccination: molecular characterization via a novel technique using ultrafiltration capillaries and mass spectrometric proteomics.DNA vaccine encoding human papillomavirus antigens flanked by a signal peptide and a KDEL sequence induces a potent therapeutic antitumor effect.Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial.From sequence to antibody: genetic immunisation is suitable to generate antibodies against a rare plant membrane protein, the KAT 1 channelA keratinocyte's course of life.Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011)Proposed mechanisms of action for prostate cancer vaccines.Topical delivery of siRNA into skin using SPACE-peptide carriers.Effective transcutaneous immunization by antigen-loaded flexible liposome in vivo.Enhanced Efficacy of a Codon-Optimized DNA Vaccine Encoding the Glycoprotein Precursor Gene of Lassa Virus in a Guinea Pig Disease Model When Delivered by Dermal Electroporation.APC-targeted immunization for the treatment of HIV-1.Intradermal DNA Electroporation Induces Cellular and Humoral Immune Response and Confers Protection against HER2/neu Tumor.DNA-vaccination via tattooing induces stronger humoral and cellular immune responses than intramuscular delivery supported by molecular adjuvants.Optimization and delivery of plasmid DNA for vaccination.Immunostimulant adjuvant patch enhances humoral and cellular immune responses to DNA immunization.Cutaneous gene therapy.Current progress of DNA vaccine studies in humans.Tolerability of intramuscular and intradermal delivery by CELLECTRA(®) adaptive constant current electroporation device in healthy volunteers.Cutaneous short-interfering RNA therapy.Delivery of DNA vaccines: an overview on the use of biodegradable polymeric and magnetic nanoparticles.Microneedles: a valuable physical enhancer to increase transdermal drug delivery.Intradermal naked plasmid DNA immunization: mechanisms of action.Transdermal immunization: biological framework and translational perspectives.Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth.RNA interference-mediated silencing of Foxo3 in antigen-presenting cells as a strategy for the enhancement of DNA vaccine potency.Noncarrier naked antigen-specific DNA vaccine generates potent antigen-specific immunologic responses and antitumor effects.Skin tattooing as a novel approach for DNA vaccine delivery.Transgene expression and local tissue distribution of naked and polymer-condensed plasmid DNA after intradermal administration in mice.Targeting dendritic cells with antigen via dendritic cell-associated promoters.A heterologous prime-boost vaccination regime using DNA and a vaccinia virus, both expressing GRA4, induced protective immunity against Toxoplasma gondii infection in mice.Intramuscular immunization with plasmid coexpressing tumour antigen and Flt-3L results in potent tumour regression.Immunization without needles.Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research.Non-human papillomaviruses for gene delivery in vitro and in vivo.
P2860
Q27489779-FAEE664F-205D-47DB-9878-3F9FA775656AQ28652580-11A559F9-3FAF-4056-A459-0507D970854EQ28740588-A986DA47-AA10-423E-A209-E56C3C1760EAQ30408029-D2ACB2EE-8274-4054-95E0-80938B2FE67CQ33228139-2858BAC8-1050-42F1-950C-F56DAF8E6A7BQ33598307-9B56A30C-AB90-4473-AC19-FF156EE929CBQ34023588-ECE558F5-AF9A-4C10-AB60-E24EFA2BB92CQ34394635-8D2807B8-FCA9-4BB1-9154-93D308E599C8Q34595069-0BF7F79F-879B-4A5E-988D-9C80FE6AC2A3Q35118834-2E42B8B2-B6E1-4426-BB4C-7F16E1C057C5Q35174754-8CEB6F22-C23B-4958-B4B8-927635EB8383Q35587915-6DAB3C7B-CEBC-4D86-8C7D-939430C9D9CAQ35656890-9A444A37-C8C8-4D3E-9E29-7C021FCD7AA4Q35826698-A78F2C39-2191-4EA8-9C5A-22C99D58CFCBQ35851829-7F339650-F622-4502-88D3-0AB0CB8A8EA7Q35890518-87597DF3-AA53-4CEB-AF86-131FF72D244EQ36494942-1845CD0F-A501-4616-8B29-5561C68C0C43Q36690285-30210D2B-0CA4-434B-B001-E7450062C6BFQ36782184-43FA7563-527C-41C9-B604-E9E266D82412Q36799389-332BFBC2-2DA1-4085-BD71-2A4CAA7FE169Q37103923-5E621260-BDCA-4172-B0A0-4BF759A1FFF3Q37530540-9743A41F-AF87-40BF-944B-ABB35DC4DF15Q37639312-71941C1A-F425-4980-92DA-C615ABE3864DQ37730793-9B3A94DF-1CAB-439B-B811-B8675A20487CQ37819486-E9B8A76C-6F7D-426C-9D2C-27F2A4090561Q37919894-CA5B7F4E-9811-40BB-93D7-989BA14342EAQ38068975-9011C767-B65F-4E4A-8306-537CF8414F2EQ39507581-DDA67A32-611F-4F67-801D-F6A81C36A933Q39627674-F990BEEC-1A35-4006-B3C7-CE89B9741537Q39862468-7BF918F5-96DA-4D6A-AE35-AE48E6741735Q41460303-407286B8-B021-4E41-A9AA-0D9512753D80Q42037581-8C4B4383-A5BF-434F-AB25-56BC367E1281Q42799142-3C8F419B-0268-4487-B0A0-DB8CCBF46307Q45403934-91E2343F-B216-4A4B-B163-A091E4B6C103Q45886869-3D1F86FB-1B18-4AF5-A2F7-D446C3F2882DQ46308392-741BD4DE-67CA-4C27-9105-7FACDE61C6C9Q51032554-467D990A-D7D8-42A6-A3E2-E303B0065668Q55415533-3BF16C18-3DA8-4898-A43C-EFE10FFF34FF
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Immunization with DNA through the skin.
@ast
Immunization with DNA through the skin.
@en
type
label
Immunization with DNA through the skin.
@ast
Immunization with DNA through the skin.
@en
prefLabel
Immunization with DNA through the skin.
@ast
Immunization with DNA through the skin.
@en
P2093
P1433
P1476
Immunization with DNA through the skin.
@en
P2093
Carl R Alving
Kristina K Peachman
Mangala Rao
P304
P356
10.1016/S1046-2023(03)00137-3
P577
2003-11-01T00:00:00Z